Supreme Court Declines Martin Shkreli’s Appeal, Upholds $64.6 Million Antitrust Judgment

The U.S. Supreme Court has declined to review an appeal by Martin Shkreli, the former pharmaceutical executive who gained notoriety for inflating drug prices. Shkreli sought to overturn a $64.6 million judgment levied against him for artificially inflating the cost of a crucial drug and attempting to block the entry of generic versions into the market. This decision effectively upholds the lower court’s ruling, which found Shkreli in violation of federal antitrust laws. For more details, you can read the original reporting from the New York Law Journal.